We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Dual Gene Activation Characterizes Breast Tumors

By Biotechdaily staff writers
Posted on 14 Nov 2006
Cancer researchers have shown that the uPAR gene is overexpressed primarily in the same breast cancer cells that overexpress another cancer gene, HER-2, adding another potential target for chemotherapeutic attack.

uPAR is a component of the plasminogen activation system, which in the healthy body is involved in tissue reorganization events such as mammary gland involution and wound healing. More...
In order to be able to reorganize tissue, it is necessary that the old tissue be degraded. An important mechanism in this degradation is the proteolysis cascade initiated by the plasminogen activation system. uPAR binds urokinase, thereby restricting plasminogen activation to the immediate vicinity of the cell membrane. The components of the plasminogen activation system have been found to be highly expressed in many malignant tumors, indicating that tumors are able to subvert the system and use it to drive metastasis.

Investigators at the University of Texas Southwestern Medical Center (Dallas, USA) analyzed both individual tumor cells (the type that escape from the tumor into the circulation system) and cancerous tissues.

They reported in the November 1, 2006, online edition of the Proceedings of the [U.S.] National Academy of Sciences that analysis of individual tumor cells indicated that uPAR amplification occurred in a significant portion of primary breast cancers. There was complete concordance between touch preps and conventional pathologic examination of HER-2 and uPAR gene status in primary tumors. There was also excellent concordance of HER-2 gene status between primary tumors and circulating tumor cells provided that acquisition of HER-2 gene amplification in the circulating tumor cells was taken into account. Unexpectedly, gene amplification of HER-2 and uPAR occurred most frequently in the same tumor cells and patients, suggesting a biologic bias and potential advantage for co-amplification. Expression of HER-2 and uPAR in primary tumors predicted gene status in 100% and 92% of patients, respectively.

"This gene, uPAR, is an important oncogene, and that is why we determined whether or not it is amplified,” explained senior author Dr. Jonathon Uhr, professor of cancer immunobiology at the University of Texas Southwestern Medical Center.

"Unexpectedly, it is usually amplified in the same tumor cell with HER-2 gene amplification. This has significant implications for treatment with targeting agents. Moreover, we stress the value of individual tumor cell analysis for providing information that cannot be obtained by conventional pathological examination.”



Related Links:
University of Texas Southwestern Medical Center

Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Melanoma Panel
UltraSEEK Melanoma Panel
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.